Elocalcitol (BXL-628): A novel, investigational therapy for the therapeutic management of benign prostatic hyperplasia

Expert Opinion on Investigational Drugs

Volumn 17, Issue 5, 2008, Pages 819-824

  Tiwari, Atul ^a  

^a JUBILANT BIOSYS LTD   (India)

Author keywords

Antiandrogens; BPH; BXL 628; Elocalcitol; Growth factors; Prostate

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANDROSTANOLONE; ANTIANDROGEN; CALCITRIOL; CALCIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; ELOCALCITOL; FINASTERIDE; GLYCOSIDE; GONADORELIN AGONIST; GROWTH FACTOR; HERBACEOUS AGENT; KERATINOCYTE GROWTH FACTOR; LUTEINIZING HORMONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RESIN; SOMATOMEDIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TESTOSTERONE; TRANSFORMING GROWTH FACTOR; VITAMIN D RECEPTOR;

APOPTOSIS; ARTICLE; BLADDER NECK STENOSIS; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; GYNECOMASTIA; HOT FLUSH; HUMAN; HYPERCALCIURIA; IMPOTENCE; INCIDENCE; LIBIDO; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MALE; MONOTHERAPY; NOCTURIA; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROGRADE EJACULATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY; URINARY FREQUENCY; URINARY URGENCY; UROFLOWMETRY;

EID: 45349093805     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.5.819     Document Type: Article

References (14)

1. Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 1999;84:3463-68
2. Caine M. The present role of α-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986;136:1-4
3. Nagle M. BioXell says 'ciao' to enlarged prostates. Available from: http://www.drugresearcher.com Last accessed [17 March 2008]
4. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43:284-9
5. Peehl DM, Skowronski RJ, Leung GK, et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805-10
6. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-60
7. Wu-Wong JR, Tian J, Goltzman D. Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Invest Drugs 2004;5:320-6
8. Colli E, Rigatti P, Montrosi F, et al. BXL-628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur J Urol 2006;49:82-6
9. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Eng J Med 1998;338:557-63
10. BioXell announces positive phase 11b results for elocalcitol in benign prostatic hyperplasia. Available from: http://www.bioxell.com/media/ press-releases/ [Last accessed 17 March 2008]
11. Crescioli C, Morelli A, Adorini L. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005;90:962-72
12. Adorini L, Penna G, Amuchastegui S, et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 2007;103:689-93
13. Crescioli C, Ferruzzi P, Caporali A, et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostatic hyperplasia. Eur J Endocrinol 2004;150:591-603
14. Tiwari A, Krishna NS, Nanda K, Chugh A. Benign prostatic hyperplasia: an insight into current investigational medical therapies. Expert Opin Invest Drugs 2005;14:1359-72